Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Stocks on the move: Bristol Myers, Abbive, and Tesla
01:11pm, Friday, 26'th Jul 2024
The Investment Committee discuss some of their stocks that are on the move today
The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induc
Why AbbVie Stock Was Cruising Higher on Thursday
04:25pm, Thursday, 25'th Jul 2024
The pharmaceutical sector mainstay posted a mixed second quarter. It topped analyst expectations for revenue and missed those for profitability, but investors were more focused on the future.
AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio
01:31pm, Thursday, 25'th Jul 2024
AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in Hu
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
11:26am, Thursday, 25'th Jul 2024
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Thursday, 25'th Jul 2024
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
10:31am, Thursday, 25'th Jul 2024
AbbVie (NYSE: ABBV ) stock is the top trending ticker on Yahoo Finance on Thursday as investors are pumped up about news from the pharmaceutical company's latest earnings report. AbbVie started its ea
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
10:30am, Thursday, 25'th Jul 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
09:47am, Thursday, 25'th Jul 2024
AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.91 per share a year ago.
AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum.
08:46am, Thursday, 25'th Jul 2024
AbbVie reported second-quarter adjusted earnings of $2.65 a share on revenue of $14.46 billion.
Is AbbVie the Best Dividend Stock for You?
07:45am, Thursday, 25'th Jul 2024
AbbVie lost its CEO last year even as its most important drug experienced a patent cliff. However, the company's business remains robust thanks to a deep lineup and rich pipeline.
AbbVie lifts annual profit forecast on strong immunology drug sales
07:39am, Thursday, 25'th Jul 2024
AbbVie raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Street expectations for the second quarter.
AbbVie Reports Second-Quarter 2024 Financial Results
07:36am, Thursday, 25'th Jul 2024
Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
04:18pm, Wednesday, 24'th Jul 2024
Arguably, there's never a bad time to consider trustworthy dividend stocks. By securing passive income, you can complement any returns you generate through speculation.
My Dividend Stock Portfolio: New June Dividend Record - 101 Holdings With 22 Buys
08:10am, Wednesday, 24'th Jul 2024
Investment activity remained high in June, focusing on BDCs aiming to increase dividend income by at least $100 each month. Adjusted dividend income in June is up 27% Y/Y and 5% vs the previous quarte
